Guggenheim maintained a Neutral rating on Johnson & Johnson (NYSE:JNJ) but increased the stock's price target from $162.00 to $166.00. The adjustment follows the release of the company's ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with ...